Equibles does not estimate personal net worth.
Get an email with a short summary when Establishment Labs Holdings Inc. publishes a filing, an earnings call transcript or a press release.
Get ESTA alertsJuan José Chacón Quirós is recorded as CEO and Board Member at Establishment Labs Holdings Inc. (ESTA). The newest filing on record that lists Juan José Chacón Quirós as CEO and Board Member at Establishment Labs Holdings Inc. (ESTA) is dated April 12, 2024. The proxy statement of Establishment Labs Holdings Inc. reports total compensation of $1,654,027 for Juan José Chacón Quirós in fiscal 2025, including a base salary of $218,918. Disclosed compensation is on record for 8 fiscal years. Juan José Chacón Quirós has spoken on 19 earnings calls across 1 company, most recently for Establishment Labs Holdings Inc. on May 7, 2025. Establishment Labs Holdings Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Establishment Labs Holdings Inc. includes Fillipo "Peter" Caldini (CEO and Board Member), Nicholas Lewin (Chairman), Raj Denhoy (CFO) and 7 others.
“Along with our first quarter earnings, we also announced today the appointment of Peter Caldini as permanent CEO of Establishment Labs. Since my retirement was announced in January, the Board of Directors has undergone an extensive review of potential candidates.”
“Revenue in the fourth quarter of 2024 totaled $44.5 million in line with our expectations and with what we preannounced in early January. For the full year, our sales were $166 million.”
“Revenue in the second quarter of 2024 totaled $44.1 million. Global demand for our products continues to stabilize and was reflected in the strong sequential improvement we saw in revenue this quarter.”
“Revenue in the fourth quarter of 2023 totaled $31.6 million, in line with the range we pre-announced in early January. While our second half results reflected lower demand for breast procedures globally, our markets are stabilizing and we are seeing improving demand, including from our distributors.”
“Revenue in the third quarter of 2023 totaled $38.5 million, in line with the third quarter of 2022. Our results this quarter reflect lower demand for breast procedures globally.”
Start not stated–present
Last confirmed April 12, 2024
Start not stated–present
Last confirmed April 12, 2024
Medical Devices · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Establishment Labs Holdings Inc. (ESTA) | Former Chief Executive Officer | $218,918 | $1,654,027 |
| 2024 | Establishment Labs Holdings Inc. (ESTA) | Former Chief Executive Officer | $733,622 | $2,601,271 |
| 2023 | Establishment Labs Holdings Inc. (ESTA) | Former Chief Executive Officer | $667,996 | $2,422,307 |
| 2022 | Establishment Labs Holdings Inc. (ESTA) | Former Chief Executive Officer | $487,720 | $2,577,107 |
| 2021 | Establishment Labs Holdings Inc. (ESTA) | Chief Executive Officer | $435,000 | $2,283,091 |
| 2020 | Establishment Labs Holdings Inc. (ESTA) | Chief Executive Officer | $337,238 | $598,158 |
| 2019 | Establishment Labs Holdings Inc. (ESTA) | Chief Executive Officer | $367,000 | $589,000 |
| 2018 | Establishment Labs Holdings Inc. (ESTA) | Chief Executive Officer | $343,984 | $483,516 |
